Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 3/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509286 | 0.85 | GBA1 (0.56) | CHRM5ADRA2CGBA1ACHECYP2D6 | |
| SCHEMBL25147628 | 0.81 | CYP2D6 (0.50) | CHRM5ADRA2CGBA1CYP2D6SMN1; SMN2 | |
| SCHEMBL10508855 | 0.81 | GBA1 (0.39) | CHRM5ADRA2CGBA1ACHECYP2D6 | |
| SCHEMBL4580897 | 0.80 | CHRM5 (0.59) | CHRM5ADRA2CGBA1ACHESMN1; SMN2 | |
| SCHEMBL4579271 | 0.80 | CHRM5 (0.59) | CHRM5ADRA2CGBA1ACHESMN1; SMN2 | |
| SCHEMBL3156763 | 0.79 | CHRM5 (0.64) | CHRM5ADRA2CGBA1ACHESMN1; SMN2 | |
| SCHEMBL2934405 | 0.78 | CYP2D6 (0.47) | CHRM5ADRA2CGBA1CYP2D6SMN1; SMN2 | |
| SCHEMBL772309 | 0.78 | CYP2D6 (0.47) | CHRM5ADRA2CGBA1CYP2D6SMN1; SMN2 | |
| SCHEMBL645562 | 0.78 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2MAPTHTT | |
| SCHEMBL3431959 | 0.78 | CYP2D6 (0.47) | CHRM5ADRA2CGBA1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452908-B2 | Amide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-11-18 | — | — | US | disclosed |
| US-6809108-B1 | SELECTIVE MUSCARINIC M3 RECEPTOR ANTAGONTS; REDUCED SIDE EFFECTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20040204369-A1 | Novel amide derivatives | MSD K.K. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1213281-B1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204369-A1 | Novel amide derivatives | CHRM3, CHRM1, CHRM2 | CHRM5 4/4885ADRA2C 42/4885GBA1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.